Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study-Reference-Cited by-同舟云学术

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study

Published:2019-12 Issue: Volume:123 Page:36-47
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Forster Martin D.,Dillon Magnus T.,Kocsis Judit,Remenár Éva,Pajkos Gabor,Rolland Frederic,Greenberg Jonathan,Harrington Kevin J.

Funder

Daiichi Sankyo, Inc.

NIHR Biomedical Research Centre

NHS Foundation Trust

National Institute for Health Research

University College London

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Epidemiologic trends in head and neck cancer and aids in diagnosis;Vigneswaran;Oral Maxillofac Surg Clin North Am,2014

2. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

3. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients;Pignon;Radiother Oncol,2009

4. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck;Argiris;Front Oncol,2017

5. National Comprehensive Cancer Network (NCCN) practice guidelines in oncology. Head and Neck Cancers. Available from: http://www.nccn.org,v2.2018.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance;Cancer Letters;2024-09

2. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review;Frontiers in Oncology;2024-08-22

3. Head and neck cancer: pathogenesis and targeted therapy;MedComm;2024-08-21

4. Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas;Cells;2024-06-11

5. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs;Cancer Drug Resistance;2024-04-29